Intellia Stock And 2 Growth Shares With Clear Earnings UpsideSimplywall·Jul 21 at 04:04 AMNTLA-3.33%PODD+3.08%
Intellia Therapeutics shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform rating and announced a $9 price target.benzinga_article·Jul 16 at 09:40 AMNTLA-3.33%
This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursdaybenzinga_article·Jul 16 at 06:15 AMIONS+1.22%PNR+1.75%
Intellia Therapeutics (NTLA) Gets a Hold from WedbushTip Ranks·Jul 10 at 09:05 AMNTLA-3.33%RANK-1.30%
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of "Hold" by AnalystsMarket Beat·Jul 9 at 03:14 AMNTLA-3.33%
Intellia CFO Edward J. Dulac III disposes of 4,677 common shares valued at $84,186PUBT·Jul 6 at 04:01 PMNTLA-3.33%
Intellia grants 53,250 inducement RSUs to 13 new hires under 2024 planPUBT·Jul 6 at 03:05 PMNTLA-3.33%
As AbbVie eyes Apogee, these biotech stocks earn the highest quant ratingsMSN·Jun 22 at 08:55 AMNTLA-3.33%LEGN-5.57%
This Stock Is Up 58% This Year. Is It too Late to Buy?Motley Fool·Jun 17 at 01:50 AMNTLA-3.33%REGN+0.63%
Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watchrttnews·Jun 15 at 09:32 PMHIMS-14.20%RGNT+0.51%
Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target ReaffirmedTip Ranks·Jun 15 at 10:15 AMNTLA-3.33%
